Harbour Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Harbour Capital Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-12,871	Closed	-$1.23M	–	251
2021 Q3	$1.23M	Buy	12,871 +1,285	+11%	+$121K	0.32%	84
2021 Q2	$1.13M	Buy	11,586 +1,215	+12%	+$116K	0.3%	91
2021 Q1	$1.01M	Buy	+10,371	New	+$1.09M	0.3%	88
2020 Q4	–	Sell	-10,156	Closed	-$977K	–	151
2020 Q3	$977K	Buy	10,156 +1,450	+17%	+$168K	0.36%	80
2020 Q2	$1.06M	Buy	8,706 +1,119	+15%	+$124K	0.43%	69
2020 Q1	$657K	Buy	7,587 +4,607	+155%	+$451K	0.33%	86
2019 Q4	$320K	Buy	+2,980	New	+$312K	0.12%	162

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Harbour Capital Advisors's NBIX Position: Q4 2021 in Review

Harbour Capital Advisors sold out of Neurocrine Biosciences (NBIX) in Q4 2021, closing a stake of 12,871 shares — an estimated $1.23M sold.

Harbour Capital Advisors first reported a position in NBIX in Q4 2019 and held it in 7 quarters. The position peaked at $1.23M in Q3 2021. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2021.

Harbour Capital Advisors reported no remaining Neurocrine Biosciences position as of Q4 2021 after selling out during the quarter.
Harbour Capital Advisors sold 12,871 Neurocrine Biosciences shares in Q4 2021, an estimated $1.23M.
Harbour Capital Advisors first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 7 quarters.
Harbour Capital Advisors's Neurocrine Biosciences position peaked at $1.23M in Q3 2021.
405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2021.

Based on Harbour Capital Advisors's 13F filing for Q4 2021, filed 12 Jan 2022.